Shawn mcCormick - 03 Apr 2025 Form 4 Insider Report for NEVRO CORP

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2025, 16:30:33 UTC
Prior SEC filing: 11 Sep 2024
Next SEC filing: 05 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Kashif Rashid, as Attorney-in-Fact for Shawn McCormick

Key filing fact

Shawn mcCormick filed Form 4 for NEVRO CORP on 03 Apr 2025.

Key facts

This page summarizes Shawn mcCormick's Form 4 filing for NEVRO CORP.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Apr 2025, 16:30.

Change

Previous filing in this sequence was filed on 11 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVRO transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -46,035
Change %: -100%
Price
Shares after: 0
Date: 03 Apr 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Shawn mcCormick is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").

Footnote F2

At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.